Back to News
Market Impact: 0.2
Annovis Bio Consensus Price Target Lowered by 16.67% to $10.71
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
The aggregate one-year analyst price target for Annovis Bio was cut 16.67% to $10.71 per share as of September 11, 2026, from $12.85 on August 25. The target reduction signals weaker analyst valuation expectations for the biotech company, though the article provides no underlying changes to earnings, clinical, or operating forecasts.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.32
Ticker Sentiment
ANVS-0.40
More News
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Hong Kong unveils first five-year plan to add jobs, homes, align closer to mainland China
- Beta Bionics prices $150M public offering at $17.25/share
- Inside South Korea’s university programs offering a direct route to Samsung and SK Hynix
- DST Global Advisors sells $6.86m in Chime Financial stock
- Why Radiant Logistics Stock Topped the Market on Tuesday